Rajan Sharma
Stock Analyst at Goldman Sachs
(3.47)
# 2,281
Out of 4,476 analysts
192
Total ratings
60%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,525p → 16,441p | $14,456.00 | +13.73% | 39 | Jul 1, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,870p → 1,890p | $2,015.00 | -6.20% | 30 | Jun 30, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €850.00 → €885.00 | $817.40 | +8.27% | 16 | Jun 17, 2026 | |
| IMTX Immatics | Rated: Buy | $11 → $12 | $9.95 | +22.61% | 4 | May 12, 2026 | |
| LON: 0MGB Genmab A/S | Reiterated: Buy | kr 2,200 → kr 2,300 | $1,861.29 | +23.57% | 5 | May 8, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $72 → $73 | $32.49 | +124.68% | 12 | May 7, 2026 | |
| GMAB Genmab | Upgraded: Buy | $26 → $31 | $28.52 | +6.96% | 4 | Apr 22, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $5.23 | -6.22% | 5 | Apr 22, 2026 | |
| DBVT DBV Technologies | Maintained: Sell | $7.25 → $5.81 | $15.82 | -63.27% | 3 | Apr 9, 2026 | |
| EPA: DBV DBV Technologies S.A. | Rated: Sell | €1.30 → €1.01 | $2.89 | -65.10% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | €25.00 → €18.00 | $24.90 | -27.71% | 8 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €304.00 → €299.00 | $257.85 | +15.96% | 7 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $813 → $910 | $939.68 | -3.16% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.63 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.66 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7.6 → $5.7 | $1.58 | +260.76% | 5 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $64.53 | -30.26% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €2.85 → €3.30 | $2.34 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $79.45 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $154 → $168 | $46.95 | n/a | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 2.00 | $6.63 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $53.66 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $127.92 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $35.13 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €90.00 → €100.00 | $170.70 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €44.00 | $51.35 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $11.44 | n/a | 2 | May 4, 2022 |
AstraZeneca PLC
Jul 1, 2026
Maintained: Buy
Price Target: 16,525p → 16,441p
Current: $14,456.00
Upside: +13.73%
GSK plc
Jun 30, 2026
Maintained: Hold
Price Target: 1,870p → 1,890p
Current: $2,015.00
Upside: -6.20%
argenx SE
Jun 17, 2026
Maintained: Buy
Price Target: €850.00 → €885.00
Current: $817.40
Upside: +8.27%
Immatics
May 12, 2026
Rated: Buy
Price Target: $11 → $12
Current: $9.95
Upside: +22.61%
Genmab A/S
May 8, 2026
Reiterated: Buy
Price Target: kr 2,200 → kr 2,300
Current: $1,861.29
Upside: +23.57%
Immunocore Holdings
May 7, 2026
Maintained: Buy
Price Target: $72 → $73
Current: $32.49
Upside: +124.68%
Genmab
Apr 22, 2026
Upgraded: Buy
Price Target: $26 → $31
Current: $28.52
Upside: +6.96%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $5.23
Upside: -6.22%
DBV Technologies
Apr 9, 2026
Maintained: Sell
Price Target: $7.25 → $5.81
Current: $15.82
Upside: -63.27%
DBV Technologies S.A.
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: $2.89
Upside: -65.10%
Apr 9, 2026
Rated: Hold
Price Target: €25.00 → €18.00
Current: $24.90
Upside: -27.71%
Mar 2, 2026
Maintained: Buy
Price Target: €304.00 → €299.00
Current: $257.85
Upside: +15.96%
Feb 26, 2026
Maintained: Buy
Price Target: $813 → $910
Current: $939.68
Upside: -3.16%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.63
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.66
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: $7.6 → $5.7
Current: $1.58
Upside: +260.76%
Jul 30, 2025
Maintained: Buy
Price Target: $35 → $45
Current: $64.53
Upside: -30.26%
Mar 21, 2025
Maintained: Hold
Price Target: €2.85 → €3.30
Current: $2.34
Upside: n/a
Oct 3, 2024
Maintained: Hold
Price Target: n/a
Current: $79.45
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $154 → $168
Current: $46.95
Upside: n/a
Jul 30, 2024
Maintained: Hold
Price Target: CHF 2.00
Current: $6.63
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $53.66
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $127.92
Upside: n/a
Dec 20, 2023
Maintained: Buy
Price Target: n/a
Current: $35.13
Upside: n/a
Feb 13, 2023
Maintained: Hold
Price Target: €90.00 → €100.00
Current: $170.70
Upside: n/a
May 16, 2022
Maintained: Hold
Price Target: €44.00
Current: $51.35
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $11.44
Upside: n/a